influenza
virus
infect
approxim
popul
result
thousand
death
year
wide
use
class
drug
treatment
clinic
influenza
neuraminidas
inhibitor
includ
oseltamivir
zanamivir
clinic
impact
drug
limit
develop
antivir
drug
resist
specif
decreas
efficaci
neuraminidas
inhibitor
report
season
influenza
novel
swineorigin
influenza
well
avian
influenza
viru
addit
initi
antivir
therapi
influenza
virusinfect
individu
beyond
first
hour
onset
influenza
symptom
associ
greater
mortal
decreas
antivir
efficaci
compar
treatment
initi
within
hour
symptom
onset
caveat
underscor
need
develop
novel
effect
influenza
therapeut
strategi
investig
intervent
strategi
shown
promis
result
influenza
virus
vitro
investig
vivo
warrant
nitric
oxid
import
cellular
signal
molecul
synthes
larginin
synthas
no
three
type
no
constitu
calciumdepend
isoform
princip
present
endotheli
neuron
cell
eno
nno
respect
induc
calciumindepend
isoform
ino
airway
no
present
varieti
cell
includ
macrophag
vascular
endotheli
cell
airway
epitheli
cell
neuron
no
activ
known
mediat
neurotransmiss
smooth
muscl
contract
mucin
secret
also
well
known
biolog
mediat
host
respons
infect
variou
inflammatori
stimuli
lp
cytokin
includ
ifng
tnf
caus
high
sustain
product
ino
depend
speci
strain
infect
dose
pathogen
entri
rout
ino
activ
result
pro
antiinflammatori
respons
cytotox
cytoprotect
review
vitro
antimicrobi
activ
demonstr
varieti
virus
includ
ectromilia
viru
vaccinia
viru
herp
simplex
type
virus
coronaviru
influenza
b
virus
studi
administr
donor
snitrosonacetylpenicillamin
snap
virusinfect
cell
significantli
reduc
viral
burden
human
trial
treatment
sever
acut
respiratori
syndrom
sar
found
inhal
ino
ppm
less
decreas
spread
intens
lung
infiltr
improv
arteri
oxygen
satur
sever
case
influenza
infect
often
associ
multisystem
organ
failur
hypoxem
respiratori
failur
includ
acut
lung
injuryacut
respiratori
distress
syndrom
aliard
requir
advanc
mechan
ventilatori
support
affect
individu
may
receiv
rescu
therapi
includ
ino
attempt
improv
outcom
howev
ino
administr
ard
secondari
viral
pneumonia
specif
report
improv
clinic
outcom
object
studi
determin
whether
ino
administr
could
reduc
viral
load
improv
surviv
murin
model
sever
influenza
inhal
deliveri
would
provid
safer
easier
deliveri
method
rather
administr
donor
ino
approv
treat
term
nearterm
neonat
hypoxem
respiratori
failur
dose
part
per
million
ppm
report
exogen
gaseou
gno
high
dose
less
ppm
five
hour
continu
exposur
elicit
nonspecif
antimicrobi
respons
broad
rang
microorgan
vitro
b
mcmullin
chittock
rosco
h
garcha
l
wang
c
miller
antimicrobi
effect
nitric
oxid
bacteria
caus
nosocomi
pneumonia
mechan
ventil
patient
icu
resp
care
pp
view
record
scopu
vivo
ppm
ino
treatment
would
result
bind
hemoglobin
form
methemoglobin
result
reduc
oxygen
transport
hypoxemia
well
potenti
elev
level
harm
metabolit
howev
miller
et
al
shown
gno
intermitt
deliveri
regimen
ppm
min
everi
hour
prevent
methemoglobinemia
reduc
potenti
host
cell
toxic
vitro
vivo
miller
c
person
commun
retain
antimicrobi
properti
vitro
evalu
abil
ino
improv
surviv
influenza
mouseadapt
strain
infect
mice
experiment
mice
inocul
intranas
lethal
dose
pfu
day
postinfect
major
mice
experiment
group
experienc
weight
loss
fig
day
postinfect
mice
began
reach
euthanasia
criteria
day
weight
day
postinfect
mice
euthan
fig
weight
loss
met
day
postinfect
infect
typic
resolv
surviv
mice
gain
weight
weight
loss
cours
infect
acceler
mice
administ
continu
ino
ppm
start
hour
prior
inocul
compar
infect
control
mice
receiv
compress
room
air
p
fig
continu
ino
administr
ppm
start
hour
prior
inocul
significantli
decreas
surviv
mice
compar
infect
control
mice
administ
compress
room
air
p
cours
infect
continu
ino
treat
mice
euthan
compar
infect
control
mice
fig
intermitt
ino
administr
ppm
min
interv
everi
hour
start
either
hour
prior
hour
postinfect
result
similar
weight
loss
kinet
fig
consequ
surviv
kinet
fig
infect
mice
compar
infect
control
mice
administ
compress
room
air
gaseou
gno
high
concentr
shown
decreas
viral
load
infect
cell
vitro
miller
c
person
commun
examin
whether
ino
could
reduc
viral
load
influenza
virusinfect
mice
ino
administ
start
hour
prior
influenza
infect
continu
either
continu
ppm
intermitt
ppm
min
everi
hour
mous
lung
harvest
peak
influenza
viral
load
lung
determin
day
postinfect
base
preliminari
studi
data
shown
sinc
ino
administ
prior
day
postinfect
abl
test
whether
ino
intermedi
ppm
high
concentr
ppm
could
prevent
either
viral
entri
viral
replic
vivo
therebi
reduc
viral
load
continu
ino
ppm
intermitt
ino
ppm
compress
room
air
administr
yield
similar
lung
viral
load
infect
mice
day
postinfect
fig
b
respect
therefor
continu
intermitt
ino
administr
fail
reduc
lung
viral
load
infect
mice
compar
infect
control
mice
administ
compress
room
air
ino
therapi
current
fda
approv
treatment
term
nearterm
neonat
hypoxem
respiratori
failur
associ
clinic
echocardiograph
evid
pulmonari
arteri
hypertens
variabl
find
report
ino
efficaci
administ
ppm
ppm
indic
use
ino
found
increas
vasodil
improv
oxygen
reduc
length
mechan
ventil
reduc
oxygen
requir
decreas
length
stay
intens
care
unit
howev
systemat
review
fail
demonstr
ino
therapi
reduc
overal
mortal
systemat
review
metaanalysi
random
control
trial
shown
ino
use
therapeut
manag
ard
result
transient
improv
arteri
oxygen
reduc
mortal
moreov
ino
therapi
ard
may
increas
risk
ino
treat
patient
develop
renal
dysfunct
despit
critic
care
specialist
survey
report
use
ino
manag
patient
ard
ontario
canada
typic
ino
administ
initi
dose
ppm
random
control
trial
observ
studi
neonat
hypox
respiratori
failur
although
fdaapprov
concentr
ppm
specif
dose
ino
proven
advantag
anoth
rather
methemoglobinemia
defin
methemoglobin
davidson
et
al
like
occur
methemoglobinemia
may
account
decreas
surviv
observ
studi
continu
ino
administr
ppm
concentr
measur
daili
cours
infect
kept
ppm
accept
human
howev
lung
toxic
may
still
explain
result
toxic
threshold
mice
may
lower
hand
given
previou
vitro
find
mcmullen
et
al
ppm
may
also
low
concentr
provid
antivir
effect
high
dose
ppm
administ
intermitt
target
airway
vessel
specif
rather
induc
antimicrobi
effect
avoid
harm
effect
high
dose
continu
ino
deliveri
ino
administ
influenza
infect
mice
manner
either
prophylact
therapeut
fail
improv
surviv
infect
mice
chang
cours
weight
loss
decreas
lung
viral
load
compar
control
mice
receiv
compress
air
therefor
although
administr
high
dose
intermitt
ino
may
reduc
harm
sideeffect
antimicrobi
activ
observ
vivo
conclus
despit
demonstr
antimicrobi
activ
influenza
viru
vitro
result
studi
support
use
ino
prophylact
treatment
strategi
reduc
viral
burden
improv
clinic
outcom
sever
influenza
vivo
furthermor
may
difficult
achiev
viricid
concentr
airway
use
ino
concentr
safe
live
host
anim
use
protocol
review
approv
univers
health
network
ontario
cancer
institut
anim
care
committe
experi
conduct
accord
institut
guidelin
anim
biosafeti
level
facil
femal
mice
week
old
obtain
jackson
laboratori
bar
harbor
usa
maintain
pathogenfre
condit
light
cycl
day
light
isofluoran
anesthesia
experiment
mice
infect
via
nasal
instil
plaqu
form
unit
pfu
influenza
stock
kindli
provid
dr
eleanor
fish
univers
health
networkunivers
toronto
pb
weight
record
daili
maximum
twelv
day
postinfect
mice
sacrif
euthanasia
criteria
met
greater
weight
loss
lung
tissu
harvest
analysi
day
postinfect
prophylact
postinfect
ino
therapi
initi
either
hour
prior
hour
postinfect
respect
mice
place
flowthrough
chamber
free
access
food
water
receiv
either
compress
room
air
continu
mix
compress
room
air
intermitt
min
everi
hour
mix
compress
room
air
soda
lime
g
suppli
chamber
ga
flow
maintain
lmin
scaveng
minim
level
respect
level
limit
ppm
continu
ino
therapi
ppm
intermitt
ino
therapi
level
measur
use
aeronox
machin
pulmonox
medic
ab
ca
lung
harvest
frozen
lung
thaw
weigh
homogen
ml
pb
sec
use
tissu
miser
homogen
fisher
scientif
ca
lung
homogen
spun
min
aliquot
store
viral
yield
titrat
influenza
viral
yield
lung
homogen
quantifi
plaqu
assay
mdck
canin
kidney
epitheli
cell
atcc
va
usa
cell
maintain
eagl
mem
atcc
va
usa
supplement
fetal
bovin
serum
antibiot
mdck
cell
cultur
cell
plate
concentr
cellsplat
well
cultur
plate
hour
later
medium
remov
mdck
cell
wash
twice
pb
dilut
lung
homogen
ad
mdck
cell
eagl
mem
duplic
incub
hour
plate
rock
everi
min
incub
ml
serumfre
eagl
mem
supplement
trypsin
sodium
bicarbon
antibiot
combin
ml
agaros
ad
well
agaros
set
plate
incub
hour
syncitia
observ
plate
fix
carnoy
fix
methanol
glacial
acet
acid
min
stain
crystal
violet
ethanol
visual
plaqu
viral
load
express
plaqu
form
unit
per
gram
lung
tissu
pfug
logrank
test
perform
kaplanmei
surviv
curv
signific
differ
weight
loss
group
assess
twoway
analysi
varianc
anova
bonferroni
posttest
perform
student
ttest
carri
viral
yield
data
assess
signific
differ
p
experiment
group
